Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.88.

A number of equities analysts have recently weighed in on FOLD shares. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Monday. Cantor Fitzgerald increased their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Guggenheim lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 22,901 shares of company stock worth $259,863. 2.20% of the stock is owned by insiders.

Institutional Trading of Amicus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Park Avenue Securities LLC acquired a new position in Amicus Therapeutics during the fourth quarter valued at approximately $123,000. Diversified Trust Co raised its stake in shares of Amicus Therapeutics by 9.7% in the 4th quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock valued at $770,000 after acquiring an additional 7,257 shares during the period. Virtu Financial LLC acquired a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $107,000. Old West Investment Management LLC boosted its position in Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after purchasing an additional 292,976 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at $702,000.

Amicus Therapeutics Trading Down 0.2 %

Shares of FOLD stock opened at $9.21 on Wednesday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -27.09 and a beta of 0.62. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average price of $9.86 and a 200 day moving average price of $10.54. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.03.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.